Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | BCL2 | P10415 | 3/20 | 0.47 |
| ▸ | FBP1 | P09467 | 10/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19801195 | 0.90 | BCL2 (0.56) | AAK1CTSSCTSKBCL2ACACB | |
| SCHEMBL18019219 | 0.89 | AAK1 (0.59) | AAK1CTSSCTSKBCL2ACACB | |
| SCHEMBL19792935 | 0.85 | BCL2 (0.49) | AAK1CTSSCTSKBCL2FBP1 | |
| SCHEMBL19792940 | 0.83 | LARS1 (0.57) | AAK1CTSSCTSKBCL2ACACB | |
| SCHEMBL18019206 | 0.80 | LARS1 (0.56) | AAK1CTSSCTSKBCL2ACACB | |
| SCHEMBL18019221 | 0.80 | LARS1 (0.55) | AAK1CTSSCTSKBCL2ACACB | |
| SCHEMBL19792936 | 0.79 | CA2 (0.60) | CTSSCTSKFBP1MAPK1 | |
| SCHEMBL6502759 | 0.78 | FBP1 (0.55) | FBP1 | |
| SCHEMBL18019207 | 0.76 | BCL2 (0.48) | AAK1CTSSCTSKBCL2MCL1 | |
| SCHEMBL19801193 | 0.74 | LARS1 (0.62) | AAK1CTSSCTSKBCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | AARS1, GARS1, ASNS | AAK1 2180/4885CTSS 436/4885CTSK 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.